• UCLA Health
  • myUCLAhealth
  • School of Medicine
UCLA Urology

UCLA Urology

UCLA Urology
  • About Us
    • Chair's Welcome
    • Awards and Recognition
    • Innovations and Technology
    • UCLA Institute of Urologic Oncology
    • Webinars
    • Contact Us
    • News and Events
    • Newsletters
    • Our History
    • Our Milestones
    • The Men's Clinic at UCLA
    • Jobs
    • Giving
  • Clinical Programs
    • Bladder Cancer
    • General Adult Urology
    • Kidney Cancer
    • Kidney Stone Center
    • Kidney Transplant Program
    • Male Urology
    • Minimally Invasive/Robotics Surgery
    • Pediatric Urology Program
    • Pelvic Medicine and Reconstruction
    • Prostate Cancer Program
    • Testicular Cancer
    • Urologic Oncology
    • Conditions Treated
  • Clinical Trials
    • Find a Doctor
    • Frequently Asked Questions (FAQ)
    • Learn More About Clinical Trials
  • For Patients
    • COVID-19 Message to Our Patients
    • Get an Expert Second Opinion
    • Telemedicine Visits Available
    • Appointment Request
    • myUCLAhealth
    • Contact Us
    • Maps and Directions
    • Clinical Updates
    • Preparing for Surgery
    • Interactive Procedure Videos
    • Patient Education
    • Patient Stories
    • Video Gallery
    • Webinars
    • Vital Signs Publications
    • UCLA Blood Donation
    • UCLA Overnight Accommodations
    • Urology Portal
  • Research
    • Bladder Cancer Research
    • Kidney Cancer Research
    • Male Urology Research
    • Pediatric Urology Research
    • Prostate Cancer Research
    • SPORE In Prostate Cancer
    • Health Services Research
    • Faculty Publications
  • Education
    • Housestaff Roster 2020-21
    • Residency
    • Fellowships
    • Medical Student Program
    • Aerial Tour: Why Choose UCLA?
  • For Healthcare Professionals
    • How to Refer a Patient
    • Physicians Updates & Clinical Updates
    • Events and CME Courses
    • eReferrals
  • Physician Directory
    • UCLA Faculty and Providers
    • Joint Appointments/Research Faculty
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

UCLA Urology

Kidney Cancer

Kidney Cancer

Kidney Cancer

  • Get an Expert Second Opinion
  • Find a Doctor
  • What is Kidney Cancer
  • Symptoms & Risk Factors
  • Diagnosis
  • Types of Kidney Cancer
  • Treatment
  • Clinical Trials
  • Why Choose UCLA
  • Institute of Urologic Oncology
  • Webinars Videos & Patient Stories
  • Get an Expert Second Opinion
  • Find a Doctor
  • What is Kidney Cancer
  • Symptoms & Risk Factors
  • Diagnosis
  • Types of Kidney Cancer
  • Treatment
  • Clinical Trials
  • Why Choose UCLA
  • Institute of Urologic Oncology
  • Webinars Videos & Patient Stories
  1. Home
  2. Clinical Programs
  3. Kidney Cancer
  4. Why Choose UCLA

Why Choose the UCLA Kidney Cancer Program

Share this

What makes the UCLA Kidney Cancer Program unique?

A Rich History 

Clinical care and research studies for kidney cancer at UCLA is facilitated through the UCLA Kidney Cancer Program. Established in 1989, it is one of the first comprehensive kidney cancer programs in the United States and has a storied history of accomplishments. The UCLA Kidney Cancer Program provides state-of-the-art care to patients with kidney cancer, in a convenient and coordinated multidisciplinary setting within the Institute of Urologic Oncology.

Multidisciplinary Kidney Cancer Care

UCLA’s Kidney Cancer Program gets referrals from the entire region for the most challenging patients. Often care of these individuals requires specialists from multiple disciplines. Members of the Institute of Urologic Oncology’s program are housed together in the Wasserman Building where they closely collaborate on a daily basis. Having joint multi-disciplinary clinics also allow patients to have a truly comprehensive care. Our patients also benefit from a bi-monthly Tumor Board in which a group of surgeons, medical oncologists, pathologists and radiologists meet to collaborate and give personalized attention to challenging cases. Additionally, our kidney surgeons have experience with targeted systemic therapy administration which gives us a unique advantage to work closely with our medical oncology team for integrated surgical/systemic therapy clinical trials.

Molecular Imaging Program

UCLA is the one of the world leaders in molecular imaging with a rich history including seminal discoveries leading to the development of Positron Emission Tomography (PET) scans. The Ahmanson Translational Imaging Division is a unique clinical and translational research program designed to provide novel diagnostic and therapeutic approaches to disease. The Division includes the Nuclear Medicine Clinic, a clinical imaging research program, a drug and probe development program with a strong underpinning in tumor biology, and a new preclinical imaging center.

The success of the Division is based on extensive collaborations within the department of molecular and medical pharmacology and across several other departments including urology and medical oncology. Several novel molecular imaging protocols are available to our kidney cancer patients including improved methods for staging and distinguishing benign from malignant tumors.

Precision Medicine in Kidney Cancer

Working with various investigators of UCLA’s Department of Pathology involved in Molecular Diagnostics, Molecular Cytogenetics, and Anatomic Pathology, we provide every patient a detailed analysis of his/her tumor samples to aid in subtyping and personalized prognostication. For rare and complicated cases, our program has become a referral center for outside centers to send complicated kidney cancer slides for expert opinion. We work closely with companies that perform genomic profiling to offer every patient the most up to date precision-medicine approaches to identify eligible candidates for participation in novel therapeutic trials. 

Hereditary Kidney Cancer Program

About 5-10% of kidney cancer is believed to have a strong genetic or hereditary component. A strong genetic component is considered when individuals have a strong family history of kidney cancer, there is early (young) age of onset, there are other personal/family history of other cancers, or the patient has bilateral or multifocal renal tumors. There are now a dozen syndromes associated with a hereditary predisposition to renal cell carcinoma. UCLA’s Hereditary Kidney Cancer Program focuses on investigation into the potential genetic causes of an individual’s kidney cancer. 

This multidisciplinary program offers a novel method of testing multiple kidney cancer genes at once as well as access to a genetic counselor to help interpret results and provide counseling. Patients with early onset kidney cancer not believed to have a hereditary component also may have a strong genetic cause of their cancer and our program offers diagnostic testing (Immunohistochemistry, FISH and cytogenetics) to assist in the characterization of these tumors. The Kidney Cancer Program leaders have specific expertise in these cancer syndromes and closely collaborate with other hereditary cancer specialists throughout the UCLA Medical Center to provide patients with the most up-to-date management strategies as well as comprehensive care coordination.

Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest